Renal denervation and symplicity HTN-3: "dubium sapientiae initium" (doubt is the beginning of wisdom)

Circulation Research

Volumn 115, Issue 2, 2014, Pages 211-214

  Papademetriou, Vasilios ^a   Tsioufis, Costas ^b   Doumas, Michael ^c  

^a GEORGETOWN UNIVERSITY   (United States)

^b UNIVERSITY OF ATHENS   (Greece)

^c ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

ambulatory blood pressure; catheter ablation; office blood pressure; renal denervation

Indexed keywords

ADRENERGIC SYSTEM; AMBULATORY MONITORING; BLOOD PRESSURE; CLINICAL RESEARCH; CLINICAL TRIAL (TOPIC); HUMAN; HYPERINSULINEMIA; KIDNEY DENERVATION; KIDNEY FAILURE; MORTALITY; PRIORITY JOURNAL; RESISTANT HYPERTENSION; REVIEW; DENERVATION; FEMALE; HYPERTENSION; MALE; RENAL ARTERY;

DENERVATION; FEMALE; HUMANS; HYPERTENSION; MALE; RENAL ARTERY;

EID: 84903935402     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.115.304099     Document Type: Review

References (42)

1. Bhatt DL, Kandzari DE, O'Neill WW, D'Agostino R, Flack JM, Katzen BT, Leon MB, Liu M, Mauri L, Negoita M, Cohen SA, Oparil S, Rocha-Singh K, Townsend RR, Bakris GL; SYMPLICITY HTN-3 Investigators. A controlled trial of renal denervation for resistant hypertension. N Engl J Med. 2014;370:1393-1401.
2. Tsioufis C, Mahfoud F, Mancia G, Redon J, Damascelli B, Zeller T, Schmieder RE. What the interventionalist should know about renal denervation in hypertensive patients: a position paper by the ESH WG on the interventional treatment of hypertension. EuroIntervention. 2014;9:1027-1035.
3. Schlaich MP, Schmieder RE, Bakris G, et al. International expert consensus statement: Percutaneous transluminal renal denervation for the treatment of resistant hypertension. J Am Coll Cardiol. 2013;62:2031-2045.
4. Schmieder RE, Redon J, Grassi G, Kjeldsen SE, Mancia G, Narkiewicz K, Parati G, Ruilope L, van de Borne P, Tsioufis C. ESH position paper: renal denervation-an interventional therapy of resistant hypertension. J Hypertens. 2012;30:837-841.
5. Symplicity HTN-2 Investigators, Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, Bohm M. Renal sympathetic denervation in patients with treatment-resistant hypertension (the Symplicity HTN-2 trial): a randomised controlled trial. Lancet. 2010; 376:1903-1909.
6. Krum H, Schlaich M, Whitbourn R, Sobotka PA, Sadowski J, Bartus K, Kapelak B, Walton A, Sievert H, Thambar S, Abraham WT, Esler M. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet. 2009;373:1275-1281.
7. Symplicity HTN-1 Investigators, Krum H, Barman N, Schlaich M, et al. Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months. J Hypertens. 2011; 57:911-917.
8. Worthley SG, Tsioufis CP, Worthley MI, Sinhal A, Chew DP, Meredith IT, Malaiapan Y, Papademetriou V. Safety and efficacy of a multi-electrode renal sympathetic denervation system in resistant hypertension: the EnligHTN I trial. Eur Heart J. 2013;34:2132-2140.
9. Krum H, Schlaich MP, Sobotka PA, Böhm M, Mahfoud F, Rocha-Singh K, Katholi R, Esler MD. Percutaneous renal denervation in patients with treatment-resistant hypertension: final 3-year report of the Symplicity HTN-1 study. Lancet. 2014;383:622-629.
10. Schlaich MP, Bart B, Hering D, et al. Feasibility of catheter-based renal nerve ablation and effects on sympathetic nerve activity and blood pressure in patients with end-stage renal disease. Int J Cardiol. 2013;168:2214-2220.
11. Hering D, Mahfoud F, Walton AS, Krum H, Lambert GW, Lambert EA, Sobotka PA, Böhm M, Cremers B, Esler MD, Schlaich MP. Renal denervation in moderate to severe CKD. J Am Soc Nephrol. 2012;23:1250-1257.
12. Ukena C, Mahfoud F, Kindermann I, Barth C, Lenski M, Kindermann M, Brandt MC, Hoppe UC, Krum H, Esler M, Sobotka PA, Böhm M. Cardiorespiratory response to exercise after renal sympathetic denervation in patients with resistant hypertension. J Am Coll Cardiol. 2011;58:1176-1182.
13. Lenski M, Mahfoud F, Razouk A, Ukena C, Lenski D, Barth C, Linz D, Laufs U, Kindermann I, Böhm M. Orthostatic function after renal sympathetic denervation in patients with resistant hypertension. Int J Cardiol. 2013;169:418-424.
14. Grassi G, Seravalle G, Quarti-Trevano F. The 'neuroadrenergic hypothesis' in hypertension: current evidence. Exp Physiol. 2010;95: 581-586.
15. Grassi G. Assessment of sympathetic cardiovascular drive in human hypertension: achievements and perspectives. Hypertension. 2009;54:690-697.
16. DiBona GF, Esler M. Translational medicine: the antihypertensive effect of renal denervation. Am J Physiol Regul Integr Comp Physiol. 2010;298:R245-R253.
17. Campese VM, Ku E, Park J. Sympathetic renal innervation and resistant hypertension. Int J Hypertens. 2011;2011:814354.
18. DiBona GF. Physiology in perspective: the wisdom of the body. Neural control of the kidney. Am J Physiol Regul Integr Comp Physiol. 2005;289:R633-R641.
19. DiBona GF, Sawin LL. Effect of renal nerve stimulation on NaCl and H2O transport in Henle's loop of the rat. Am J Physiol. 1982;243: F576-F580. (Pubitemid 13167132)
20. Smyth DD, Umemura S, Pettinger WA. Renal nerve stimulation causes alpha 1-adrenoceptor-mediated sodium retention but not alpha 2-adrenoceptor antagonism of vasopressin. Circ Res. 1985;57:304-311. (Pubitemid 15247786)
21. Osborn JL, DiBona GF, Thames MD. Beta-1 receptor mediation of renin secretion elicited by low-frequency renal nerve stimulation. J Pharmacol Exp Ther. 1981;216:265-269. (Pubitemid 11130182)
22. O'Hagan KP, Thomas GD, Zambraski EJ. Renal denervation decreases blood pressure in DOCA-treated miniature swine with established hypertension. Am J Hypertens. 1990;3:62-64. (Pubitemid 20077356)
23. Atherton DS, Deep NL, Mendelsohn FO. Micro-anatomy of the renal sympathetic nervous system: a human postmortem histologic study. Clin Anat. 2012;25:628-633.
24. Kandzari DE, Bhatt DL, Sobotka PA, O'Neill WW, Esler M, Flack JM, Katzen BT, Leon MB, Massaro JM, Negoita M, Oparil S, Rocha-Singh K, Straley C, Townsend RR, Bakris G. Catheter-based renal denervation for resistant hypertension: rationale and design of the SYMPLICITY HTN-3 Trial. Clin Cardiol. 2012;35:528-535.
25. Doumas M, Anyfanti P, Bakris G. Should ambulatory blood pressure monitoring be mandatory for future studies in resistant hypertension: a perspective. J Hypertens. 2012;30:874-876.
26. Papademetriou V, Rashidi AA, Tsioufis C, Doumas M. Renal nerve ablation for resistant hypertension: how did we get here, present status, and future directions. Circulation. 2014;129:1440-1451.
27. Mancia G, Parati G. Office compared with ambulatory blood pressure in assessing response to antihypertensive treatment: a meta-analysis. J Hypertens. 2004;22:435-445. (Pubitemid 38368472)
28. Mahfoud F, Ukena C, Schmieder RE, et al. Ambulatory blood pressure changes after renal sympathetic denervation in patients with resistant hypertension. Circulation. 2013;128:132-140.
29. Persu A, Jin Y, Azizi M, et al.; European Network COordinating research on Renal Denervation (ENCOReD). Blood pressure changes after renal denervation at 10 European expert centers. J Hum Hypertens. 2014;28:150-156.
30. Fadl Elmula FE, Hoffmann P, Larstorp AC, Fossum E, Brekke M, Kjeldsen SE, Gjonnass E, Hjornholm U, Kjaer VN, Rostrup M, Os I, Stenehjem A, Hoieggen A. Adjusted drug treatment is superior to renal sympathetic denervation in patients with true treatment-resistant hypertension. Hypertension. 2014;63:991-999.
31. Tsioufis C. Hypertension: is the sham procedure 'toxic' for renal denervation? Nat Rev Nephrol. 2014;10:186-187.
32. Esler M. Renal denervation for hypertension: observations and predictions of a founder. Eur Heart J. 2014;35:1178-1185.
33. Schirmer SH, Sayed MM, Reil JC, Ukena C, Linz D, Kindermann M, Laufs U, Mahfoud F, Böhm M. Improvements in left ventricular hypertrophy and diastolic function following renal denervation: effects beyond blood pressure and heart rate reduction. J Am Coll Cardiol. 2014;63:1916-1923.
34. Mahfoud F, Urban D, Teller D, et al. Effect of renal denervation on left ventricular mass and function in patients with resistant hypertension: data from a multi-centre cardiovascular magnetic resonance imaging trial [published online ahead of print March 6, 2014]. Eur Heart J. http://eurheartj. oxfordjournals.org/content/early/2014/03/05/eurheartj. ehu093.abstract. doi: 10.1093/eurheartj/ehu093.
35. Mahfoud F, Schlaich M, Kindermann I, Ukena C, Cremers B, Brandt MC, Hoppe UC, Vonend O, Rump LC, Sobotka PA, Krum H, Esler M, Böhm M. Effect of renal sympathetic denervation on glucose metabolism in patients with resistant hypertension: a pilot study. Circulation. 2011;123:1940-1946.
36. Witkowski A, Prejbisz A, Florczak E, Kdziela J, liwiski P, Biele P, Michaowska I, Kabat M, Warcho E, Januszewicz M, Narkiewicz K, Somers VK, Sobotka PA, Januszewicz A. Effects of renal sympathetic denervation on blood pressure, sleep apnea course, and glycemic control in patients with resistant hypertension and sleep apnea. Hypertension. 2011;58:559-565.
37. Ukena C, Bauer A, Mahfoud F, Schreieck J, Neuberger HR, Eick C, Sobotka PA, Gawaz M, Böhm M. Renal sympathetic denervation for treatment of electrical storm: first-in-man experience. Clin Res Cardiol. 2012;101:63-67.
38. Tsioufis C, Papademetriou V, Tsiachris D, Dimitriadis K, Kasiakogias A, Kordalis A, Antonakis V, Kefala A, Thomopoulos C, Kallikazaros I, Lau EO, Stefanadis C. Drug-resistant hypertensive patients responding to multielectrode renal denervation exhibit improved heart rate dynamics and reduced arrhythmia burden [published online ahead of print March 13, 2014]. J Hum Hypertens. http://www.nature.com/jhh/journal/vaop/ ncurrent/full/jhh201414a.html. doi: 10.1038/jhh.2014.14.
39. Ormiston JA, Watson T, van Pelt N, Stewart R, Haworth P, Stewart JT, Webster MW. First-in-human use of the OneShot renal denervation system from Covidien. EuroIntervention. 2013;8:1090-1094.
40. Ahmed H, Neuzil P, Skoda J, Petru J, Sediva L, Schejbalova M, Reddy VY. Renal sympathetic denervation using an irrigated radiofrequency ablation catheter for the management of drug-resistant hypertension. JACC Cardiovasc Interv. 2012;5:758-765.
41. Bunte MC, Infante de Oliveira E, Shishehbor MH. Endovascular treatment of resistant and uncontrolled hypertension: therapies on the horizon. JACC Cardiovasc Interv. 2013;6:1-9.
42. Tsioufis C, Dimitriadis K, Thomopoulos C, Doumas M, Papademetriou V, Stefanadis C. Renal and cardiac effects of renal sympathetic denervation and carotid baroreceptor stimulation. Curr Vasc Pharmacol. 2014;12:55-62.